{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008498","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.377106+00:00","generated_at":"2026-06-17T09:27:07.352392+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reviva reports FY2022 net loss of $24.3M; cash runway through Q3 2023; Phase 3 topline data expected mid-2023","bullets":["Net loss of $24.3M ($1.25 per share) vs $8.5M ($0.58 per share) in FY2021.","Cash and equivalents $18.5M as of Dec 31, 2022, down from $29.7M; cash expected to fund operations through Q3 2023.","Over 50% of ~400 patients enrolled in pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.","Completed majority of prelaunch studies for NDA submission; positive drug-drug interaction data reported.","May initiate Phase 2a studies in bipolar disorder, MDD, ADHD in H2 2023 subject to additional financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008498","json":"https://secwatch.observer/filing/0001437749-23-008498.json","markdown":"https://secwatch.observer/filing/0001437749-23-008498.md","text":"https://secwatch.observer/filing/0001437749-23-008498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/0001437749-23-008498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/rvph20230327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:27:07.352392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2630d61a80d5ed984204bafdbef675da47a899cc","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported full year ended December 31, 2022 results: net income approximately $24.3 million, EPS $1.25 per share.","evidence_excerpt":"For the year ended December 31, 2022, net loss was approximately $24.3 million, or $1.25 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/0001437749-23-008498-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Net income","value":"approximately $24.3 million"},{"label":"EPS","value":"$1.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}